Iron Deficiency Anemia - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 68
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: IA67737E46DEN
Leaflet:

Download PDF Leaflet

Iron Deficiency Anemia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Iron Deficiency Anemia - Pipeline Review, H2 2016’, provides an overview of the Iron Deficiency Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
  • The report reviews pipeline therapeutics for Iron Deficiency Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Iron Deficiency Anemia therapeutics and enlists all their major and minor projects
  • The report assesses Iron Deficiency Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Iron Deficiency Anemia Overview
Therapeutics Development
Pipeline Products for Iron Deficiency Anemia - Overview
Pipeline Products for Iron Deficiency Anemia - Comparative Analysis
Iron Deficiency Anemia - Therapeutics under Development by Companies
Iron Deficiency Anemia - Therapeutics under Investigation by Universities/Institutes
Iron Deficiency Anemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Iron Deficiency Anemia - Products under Development by Companies
Iron Deficiency Anemia - Products under Investigation by Universities/Institutes
Iron Deficiency Anemia - Companies Involved in Therapeutics Development
Galenica Ltd.
Johnson & Johnson
Novartis AG
Panion & Bf Biotech Inc
Pieris Pharmaceuticals, Inc.
Rockwell Medical, Inc.
Iron Deficiency Anemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CSJ-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Repalce Iron for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric pyrophosphate citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-42905343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-8679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Iron Deficiency Anemia - Dormant Projects
Iron Deficiency Anemia - Product Development Milestones
Featured News & Press Releases
Apr 28, 2016: Rockwell Medical Announces Triferic Presentation "Overcoming Functional Iron Deficiency in Your Hemodialysis Patients" at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston
Mar 29, 2016: Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease
Mar 21, 2016: China FDA Accepts Rockwell Medical’s Triferic Drug Submission for Commercialization in China
Feb 22, 2016: Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia
Jan 19, 2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 - May 1, 2016 in Boston, MA
Dec 01, 2015: Rockwell Medical to Present at Oppenheimer 26th Annual Healthcare Conference
Nov 30, 2015: Rockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement
Oct 28, 2015: Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at American Society of Nephrology Meeting November 2015
Oct 06, 2015: Rockwell Medical Announces Four Triferic Posters Accepted for Presentation at American Society of Nephrology Clinical Meeting November 2015
Sep 09, 2015: Rockwell Medical Announces the U.S. Commercial Launch of Triferic
Aug 31, 2015: A meta-analysis on individual-patient data reports that Ferinject treatment of iron deficiency in patients with systolic chronic heart failure is associated with reduced rates of cardiovascular hospitalisations and cardiovascular deaths
Jul 15, 2015: Rockwell Medical Announces Triferic Phase 3 CRUISE Studies Published in Nephrology Dialysis Transplantation
Jul 13, 2015: Rockwell Medical Announces Triferic ESA-Sparing PRIME Study Published in Kidney International
May 12, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Presentations at the 52nd ERA-EDTA Congress May 28-31, 2015 in London, UK
May 05, 2015: Rockwell Medical to Present at Bank of America Merrill Lynch 2015 Health Care Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Iron Deficiency Anemia, H2 2016
Number of Products under Development for Iron Deficiency Anemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Iron Deficiency Anemia - Pipeline by Galenica Ltd., H2 2016
Iron Deficiency Anemia - Pipeline by Johnson & Johnson, H2 2016
Iron Deficiency Anemia - Pipeline by Novartis AG, H2 2016
Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H2 2016
Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals, Inc., H2 2016
Iron Deficiency Anemia - Pipeline by Rockwell Medical, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Iron Deficiency Anemia - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Iron Deficiency Anemia, H2 2016
Number of Products under Development for Iron Deficiency Anemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Galenica Ltd.
Johnson & Johnson
Novartis AG
Panion & Bf Biotech Inc
Pieris Pharmaceuticals, Inc.
Rockwell Medical, Inc.
Skip to top


Ask Your Question

Iron Deficiency Anemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: